Exabis Library
Welcome to the e-CCO Library!
OP25: Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative data
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP26: Programmable probiotic local delivery of anti-TNF-α nanobody to alleviate DSS-induced colitis
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP26: The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative Colitis
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP26: The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative Colitis
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy Volunteers
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s Disease: Final results from the Phase 2 open-label extension study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM